Special Issue "HIV/AIDS Prevention Formulation Design and Optimization and Its Pharmacokinetic-Pharmacodynamic Evaluation"
Deadline for manuscript submissions: 30 November 2023 | Viewed by 1792
Interests: HIV prevention; pre-exposure prophylaxis; multipurpose prevention technologies; preclinical research
Daily oral re-exposure prophylaxis (PrEP) has been highly effective in preventing HIV acquisition when taken as prescribed, although inadequate adherence reduces efficacy and public health benefits. The development of new long-acting PrEP modalities that do not require frequent dosing is being actively pursued in order to overcome suboptimal drug adherence to daily oral PrEP. A biomonthly injection of cabotegravir formulated as a nanoparticle suspension for intramuscular injection was the first long-acting regimen approved by the Food and Drug Administration (FDA) for PrEP in men and women.
This Special Isssue invites original research papers, communications or review articles that focus on the development of new long-acting drug formulations and controlled/extended release technologies for HIV PrEP, including (but not limited to) prodrug modifications, subdermal/subcutaneous implants, subcutaneous/intramuscular injectables, microarray patches, intravaginal rings, vaginal gels, inserts, and films. Articles studying pharmacokinetic/pharmacodynamic relationships in animal models are also considered as highly relevant for this Special Issue.
Dr. José Gerardo Garcìa-Lerma
Dr. S. Rahima Benhabbour
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- HIV pre-exposure prophylaxis (PrEP)
- long-acting PrEP
- drug delivery systems
- prodrug modification
- in vitro/in vivo correlation (IVIVC)
- animal models